# Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

> **NCT00456248** · PHASE4 · TERMINATED · sponsor: **Kadmon Corporation, LLC** · enrollment: 5 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Infergen and ribavirin

## Key facts

- **NCT ID:** NCT00456248
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2012-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456248, "Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00456248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*